Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications

Table 1

Changes in differences between prices for the originator and biosimilar insulin glargine 100 IU/ml across Europe in recent years (based on local costs/DDD).

(a)

	Albania	Austria	B & H	Bulgaria	Catalonia (Spain)
% difference originator vs. biosimilar price
Launch of the biosimilar	Not applicable	Not applicable	No difference	4.7%	30.0%
Latest difference	Not applicable	Not applicable	7.9%	5.7%	Similar
% price change over time (from 2014/2015 to 2020)
Originator	-32.0%	No change	-11.3%	-10.8%	-23.1%
Biosimilar	Not applicable	Not applicable	-17.1%	-11.7%	No change

(b)

	Czech Republic	Estonia	Hungary	Italy	Latvia	Lithuania
% difference originator vs. biosimilar price
Launch of the biosimilar	17.1%	16.4%	28.2%	Not recorded	Not applicable	12.3%
Latest difference	Similar	7.1%	1.6%	31.6%	Not applicable	Similar
% price change over time (from 2014/2015 to 2020)
Originator	-25.5%	-24.9%	-21.2%	52.3%	-14.4%	-21.1%
Biosimilar	-7.7%	Stable	1.2%	Not recorded	Not applicable	-6.8%

(c)

	Malta	Norway	Poland	Scotland	Slovenia	Sweden
% difference originator vs. biosimilar price
Launch of the biosimilar	Not applicable	12.1%	24.7%	18.1%	22.9%	13.6%
Latest difference	Not applicable	5.9%	0.2%	7.5%	9.9%	0.6%
% price change over time (from 2014/2015 to 2020)
Originator	-61.3%	-3.6%	-31.1%	-9.0%	-20.3%	-12.7%
Biosimilar	Not applicable	2.1%	-6.5%	No change	No change	-1.4%